Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04703790
Other study ID # AAAT5154
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 7, 2021
Est. completion date February 18, 2022

Study information

Verified date March 2023
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The overall purpose of this study is to address the factors associated with an individual's personal willingness to get the vaccine and attitudes about potential public policy approaches to implementation of a Coronavirus Disease 2019 (COVID-19) vaccine. Additionally, to evaluate how these attitudes change over time. The 1200 participants will be recruited by Ipsos (Ipsos KnowledgePanel®) from their nationally representative panel to participate in a survey at Time 1 and 1 year later. The information collected will include demographics, health status, household composition, experiences with COVID-19, attitudes about vaccines in general, COVID-19 vaccine specific attitudes, willingness to get a COVID-19 vaccine acceptability, and attitudes regarding COVID-19 vaccine mandates. The investigators anticipate that those who live in urban areas and who are older, have greater knowledge of COVID-19, who have known someone who was hospitalized for COVID-19, and have generally positive attitudes about vaccines will be more willing to get a vaccine. The primary reasons for willingness will be personal safety and desire to return to normal activities. The investigators also anticipate that those who vary on socio-demographics (e.g., live in urban areas, have more liberal political views), have greater knowledge of COVID-19, who have known someone who was hospitalized for COVID- 19, and have generally positive attitudes about vaccines will be more supportive of mandatory vaccination strategies. The investigators anticipate that attitudes will change over time in response to the current status of the pandemic and of available data about the vaccine's efficacy and safety.


Description:

The overall objective is to address attitudes about potential public policy approaches to implementation of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine and the factors associated with an individual's personal willingness to get the vaccine once available, and to assess how these attitudes change over time. First specific aim: 1a. To describe participants' perceptions of public health strategies including mandatory vaccination requirements (e.g., travel, school attendance, work place requirements (e.g., schools, health care facilities, offices), working in a health care facility, health care providers, living in residential facilities) and targeted age groups (e.g., children, adolescents, adults, elderly). 1. b. To determine how attitudes about strategies are related to socio-demographic characteristics (e.g., age, education, race/ethnicity, political views and political party affiliation, household structure), knowledge of SARS-CoV-2, personal experience with the infection, and other vaccine attitudes. Example hypothesis: Those who vary on socio-demographics (e.g., live in urban areas, have more liberal political views), have greater knowledge of SARS-CoV-2, who have known someone who was hospitalized for SARS-CoV-2, and have generally positive attitudes about vaccines will be more supportive of mandatory vaccination strategies. Second specific aim: 2. a. To determine the relationship of socio-demographic characteristics (e.g., age, education, race/ethnicity, political views and political party affiliation, household structure), knowledge of SARS-CoV-2, personal experience with the infection, and other vaccine attitudes with willingness to get the vaccine. 2b. To evaluate the primary reasons driving vaccine acceptance including safety issues (personal, family, or global), desire to return to normal activities (e.g., school, work, or social events), and desire to no longer need to wear a mask. Example hypotheses: Those who vary on socio-demographic characteristics (e.g., live in urban areas, who are older), have greater knowledge of SARS-CoV-2, who have known someone who was hospitalized for SARS-CoV-2, and have generally positive attitudes about vaccines will be more willing to get a vaccine. The primary reasons for willingness will be personal safety and desire to return to normal activities. Third specific aim: This specific aim focuses on how the findings from aim 1 and aim 2 change over time. 3a. To evaluate how national level perceptions of public health strategies (aim 1) and an individual's personal willingness to get the vaccine (aim 2) change over time. Given the unknown trajectory, there are several possible scenarios. For example, if nationally there is a decrease in new infections with lifting of the restrictions then the investigators hypothesize that there will be an overall decrease in support for mandatory strategies and in willingness to accept the vaccine. Alternatively, if new infections are rising and restrictions are in place, then there will be an overall increase in acceptability. The investigators are also prepared to adapt our surveys should one or more vaccines become licensed and available prior to the time 1 or time 2 survey. 3b. The investigators will explore whether changes in perceptions of public health strategies (aim 1) and an individual's personal willingness to get the vaccine (aim 2) vary based on relevant socio-demographic characteristics (e.g., region of the country, political views and political party affiliation, household structure, race/ethnicity) and, when appropriate, changes within those characteristics (e.g., when rates of infections are changing differentially across regions). The investigators also will explore whether changes in perceptions of public health strategies (aim 1) and an individual's personal willingness to get the vaccine (aim 2) vary based on perceptions of societal events. For example, the investigators will evaluate if changes in vaccine attitudes are associated with regional differences in whether cases are increasing or decreasing; changes in household structure (e.g., the presence of elders in the home); or perceptions of media reports.


Recruitment information / eligibility

Status Completed
Enrollment 1208
Est. completion date February 18, 2022
Est. primary completion date April 22, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age and older - Able to read English and Spanish - Panelists with Ipsos (KnowledgePanel) Exclusion Criteria: - 17 years of age and younger - Not able to read English or Spanish - Not a member of Ipsos (KnowledgePanel)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Columbia University Irving Medical Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Columbia University Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vaccination or intention to get vaccinated for COVID-19 Participants vaccination status or intent to get vaccinated for COVID-19 will be measured via survey items. Baseline, 1 year
Secondary Attitudes toward mandates for COVID-19 vaccines Participants self report of attitudes on survey Baseline, 1 year
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3